Abstract #511: HS CRP in Acute Coronary Syndrome

2016 ◽  
Vol 22 ◽  
pp. 121-122
Author(s):  
Mukhyaprana Prabhu ◽  
Shyny Reddy ◽  
Ranjan Shetty ◽  
V.B. Mohan ◽  
Weena Stanley
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Hs Crp

scholarly journals Effect of atorvastatin on hs-CRP in acute coronary syndrome

2008 ◽  
Vol 66 (3) ◽  
pp. 411-413 ◽  
Author(s):  
Ankur Gupta ◽  
Dinesh K. Badyal ◽  
Prem P. Khosla ◽  
Bharti Uppal ◽  
Thannikot M. Jaison ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Hs Crp

scholarly journals Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non–ST-Segment Elevation Acute Coronary Syndrome

2017 ◽  
Vol 63 (7) ◽  
pp. 1214-1226 ◽  
Author(s):  
Mark Y Chan ◽  
Megan L Neely ◽  
Matthew T Roe ◽  
Shaun G Goodman ◽  
David Erlinge ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
Cardiovascular Events ◽  
Basic Unit ◽  
St Segment Elevation ◽  
Time Points ◽  
Coronary Syndrome ◽  
St Segment ◽  
Elevation Acute Coronary Syndrome ◽  
Hs Crp

Abstract BACKGROUND There are conflicting data on whether changes in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) concentrations between time points (delta NT-proBNP and hs-CRP) are associated with a change in prognosis. METHODS We measured NT-proBNP and hs-CRP at 3 time points in 1665 patients with non–ST-segment elevation acute coronary syndrome (NSTEACS). Cox proportional hazards was applied to the delta between temporal measurements to determine the continuous association with cardiovascular events. Effect estimates for delta NT-proBNP and hs-CRP are presented per 40% increase as the basic unit of temporal change. RESULTS Median NT-proBNP was 370.0 (25th, 75th percentiles, 130.0, 996.0), 340.0 (135.0, 875.0), and 267.0 (111.0, 684.0) ng/L; and median hs-CRP was 4.6 (1.7, 13.1), 1.9 (0.8, 4.5), and 1.8 (0.8, 4.4) mg/L at baseline, 30 days, and 6 months, respectively. The deltas between baseline and 6 months were the most prognostically informative. Every +40% increase of delta NT-proBNP (baseline to 6 months) was associated with a 14% greater risk of cardiovascular death (adjusted hazard ratio (HR) 1.14, 95% CI, 1.03–1.27) and with a 14% greater risk of all-cause death (adjusted HR 1.14, 95% CI, 1.04–1.26), while every +40% increase of delta hs-CRP (baseline to 6 months) was associated with a 9% greater risk of the composite end point (adjusted HR 1.09, 95% CI, 1.02–1.17) and a 10% greater risk of myocardial infarction (adjusted HR 1.10, 95%, CI 1.00–1.20). CONCLUSIONS Temporal changes in NT-proBNP and hs-CRP are quantitatively associated with future cardiovascular events, supporting their role in dynamic risk stratification of NSTEACS. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier NCT00699998

The Association between hs-CRP Levels with GRACE Score in Acute Coronary Syndrome Patients in H. Adam Malik Medan Central General Hospital

2021 ◽  
Vol 8 (8) ◽  
pp. 220-226
Author(s):  
Putri Gaby Yosephine ◽  
Refli Hasan ◽  
Rahmad Isnanta
Keyword(s):  
Acute Coronary Syndrome ◽  
General Hospital ◽  
Spearman Correlation ◽  
Correlation Test ◽  
Coronary Syndrome ◽  
Wide Range ◽  
Significant Difference ◽  
Spearman Correlation Test ◽  
Hs Crp ◽  
Grace Score

Objective: Acute coronary syndrome (ACS) describes a wide range of myocardial ischemia, which is always associated with the rupture of atherosclerotic plaques in coronary arteries. CRP has been shown to be a risk predictor of ACS. GRACE score has been associated with predicting early and late death in ACS patients. Therefore, this study aim to investigate the association between high sensitivity C-reactive protein (hs-CRP) levels with GRACE score in ACS patients. Methods: This study was a retrospective analytic study. The study population was acute coronary syndrome patients in central general hospital of H. Adam Malik, Medan city and 51 patients who met the inclusion and exclusion criteria. Data analysis was calculated using univariate and bivariate analysis. A correlation test was carried out using Spearman correlation test to determine the association between hs-CRP levels with GRACE score in ACS patients. Results: There were 51 samples included in the study. There was a significant difference (p = 0.005) in the mean hs-CRP levels in UAP, NSTEMI, and STEMI subjects. In contrast, there was no significant difference in GRACE score among the three ACS diagnoses. For the association of hs-CRP levels with GRACE score in all subjects, the Spearman correlation test showed a significant correlation between hs-CRP levels with GRACE score (p < 0.001) with a correlation coefficient (r) of 0.588. Conclusion: There was a significant association between serum hs-CRP levels with GRACE score and the higher hs-CRP levels, followed by a higher GRACE score. Keywords: Acute coronary syndrome, GRACE score, hs-CRP.

scholarly journals Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study

2020 ◽  
Vol 58 (12) ◽  
pp. 2099-2106 ◽  
Author(s):  
Victor J. van den Berg ◽  
Victor A.W.M. Umans ◽  
Milos Brankovic ◽  
Rohit M. Oemrawsingh ◽  
Folkert W. Asselbergs ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Risk Prediction ◽  
Stable Coronary Artery Disease ◽  
Reference Value ◽  
High Sensitivity ◽  
Biological Variability ◽  
Cardiac Events ◽  
Coronary Syndrome ◽  
Hs Crp ◽  
Artery Disease

Abstract Objectives Details of the biological variability of high-sensitivity C-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and ST2 are currently lacking in patients with acute coronary syndrome (ACS) but are crucial knowledge when aiming to use these biomarkers for personalized risk prediction. In the current study, we report post-ACS kinetics and the variability of the hs-CRP, NT-proBNP and ST2. Methods BIOMArCS is a prospective, observational study with high frequency blood sampling during 1 year post-ACS. Using 1507 blood samples from 191 patients that remained free from adverse cardiac events, we investigated post-ACS kinetics of hs-CRP, NT-proBNP and ST2. Biological variability was studied using the samples collected between 6 and 12 months after the index ACS, when patients were considered to have stable coronary artery disease. Results On average, hs-CRP rose peaked at day 2 and rose well above the reference value. ST2 peaked immediately after the ACS but never rose above the reference value. NT-proBNP level rose on average during the first 2 days post-ACS and slowly declined afterwards. The within-subject variation and relative change value (RCV) of ST2 were relatively small (13.8%, RCV 39.7%), while hs-CRP (41.9%, lognormal RCV 206.1/-67.3%) and NT-proBNP (39.0%, lognormal RCV 185.2/-64.9%) showed a considerable variation. Conclusions Variability of hs-CRP and NT-proBNP within asymptomatic and clinically stable post-ACS patients is considerable. In contrast, within-patient variability of ST2 is low. Given the low within-subject variation, ST2 might be the most useful biomarker for personalizing risk prediction in stable post-ACS patients.

scholarly journals Intensive Statin Therapy in NSTE-ACS Patients Undergoing PCI: Clinical and Biochemical Effects

2015 ◽  
Vol 42 (6) ◽  
pp. 528-536 ◽  
Author(s):  
Mohamed Shehata ◽  
George Fayez ◽  
Ahmed Nassar
Keyword(s):  
Acute Coronary Syndrome ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Cardiac Events ◽  
Ventricular Ejection Fraction ◽  
Coronary Syndrome ◽  
Adverse Cardiac Events ◽  
Significant Difference ◽  
Hs Crp ◽  
Group B

Early initiation of statin therapy in acute coronary syndrome patients has a favorable prognostic impact because of its anti-inflammatory and antithrombotic properties. In this study, we explored the effect of atorvastatin-loading, followed by intensive atorvastatin therapy, on clinical and biochemical outcomes in non-ST-segment-elevation acute coronary syndrome patients who were scheduled for percutaneous coronary intervention. We prospectively enrolled 140 patients (mean age, 56 ± 9 years, 68% men). Once eligible, patients were randomly assigned to receive either a moderate 20-mg daily dose of atorvastatin (Group A) or a 160-mg loading dose followed by an intensified 80-mg daily dose (Group B). High-sensitivity C-reactive protein (hs-CRP) levels were recorded before and after intervention. Evaluation after 6 months included hs-CRP levels, left ventricular systolic function, and major adverse cardiac events. We found no significant difference between the 2 groups in regard to the interventional data. However, blood sampling after coronary intervention, and again 6 months later, revealed a significant decline in mean hs-CRP level among Group B patients (P &lt;0.001). Moreover, patients in Group B manifested a higher left ventricular ejection fraction than did patients in Group A (P &lt;0.05). After 6 months, we found no significant difference between groups in the incidence of major adverse cardiac events. We conclude that intensive atorvastatin therapy in non-ST-segment-elevation acute coronary syndrome patients is associated with lower hs-CRP levels and with higher left ventricular ejection fraction after 6 months, with no significant impact on adverse cardiac events.

Sign in / Sign up

Export Citation Format

Share Document